Pharmacist-led, digitally enabled transitional care after acute myocardial infarction: design and baseline characteristics of the AMI-HOPE nationwide stepped-wedge trial
Clicks: 3
ID: 318084
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #47 of 55 articles by views in European Heart Journal - Digital Health
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Aims To describe the design of AMI-HOPE, a pharmacist-led, digitally enabled transitional care intervention for patients after acute myocardial infarction (AMI), and its nationwide stepped-wedge cluster-randomized evaluation across Singapore's public healthcare system. Methods AMI-HOPE uses the Health Discovery+ (HD+) platform for remote vital signs monitoring, rule-based alerts, pharmacist-led teleconsultations, and automated patient education. In this pragmatic, open-label trial across 3 health clusters (7 hospitals, 18 polyclinics), hospitals crossed over from standard cardiologist-led care to intervention at 3-month intervals. Target N=1,512 (1:1 ratio); primary outcome is a hierarchical WIN-ratio composite (CV death, MI, stroke, CV readmissions, LDL-C, SBP, HbA1c, PROMs). Secondary outcomes include GDMT titration/adherence, LVEF, and cost-effectiveness. Results Enrolment completed in September 2025 (N=1,634 randomized; 810 control, 824 intervention). Baseline characteristics (N=1,492 in follow-up) showed a median age of 59 years, 12% female, 61% Chinese ethnicity. Twelve-month follow-up will complete on 30th September 2026. Conclusions AMI-HOPE demonstrates a scalable, digitally enabled model shifting early post-AMI care from specialist-led clinics to pharmacists with remote monitoring. This nationwide trial evaluates its clinical efficacy, implementation, and value at population scale. ClinicalTrials.gov: NCT07443982
| Reference Key |
openalex_W7165456085
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Melody Wang, Zhi-Zhen Lim, S P Chan, Zhen-Long Teo, Sock-Hwee Tan, Vinay Panday, Ho Jien Sze, Yee-May Wong, G C Chang, Faclin Ng, Imran Syed, Patrick Lim, Zijuan Huang, Ziliang Lim, Valerie Teo, Ian Phoon, Kalih Kunarso, Siang-Chew Chai, Kai-Rong Siau, Yew-Seng Kwan, Samuel Ho, Laurane Lim, Marvin Sim, Hui-Rei Yap, Wan-Lin Oh, Hui-Ping Chong, Angela Yeo, Praveen Deorani, Robert Morris, Hee‐Hwa Ho, D J Hausenloy, Hwee-Lin Wee, Doreen Tan, Mark Y. Chan |
| Journal | European Heart Journal - Digital Health |
| Year | 2026 |
| DOI |
10.1093/ehjdh/ztag094
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.